Press Releases.

Regulus Appoints Allison Wey as Vice President, Investor Relations & Corporate Communications

LA JOLLA, Calif., May 23, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that Allison Wey has been appointed Vice President, Investor Relations and Corporate Communications.  Ms. Wey brings over 25 years of experience in investor relations, corporate communications, media relations and investment banking.

Regulus Therapeutics Inc. Logo

"Allison's broad background in investor relations will prove valuable as the company's pipeline matures," said Jay Hagan, Chief Operating Officer of Regulus.  "We are pleased to welcome Allison, and we look forward to her contributions in communicating the strong potential of Regulus' pipeline."

"Regulus is leading the way in developing important new therapies focused on microRNA dysregulation to treat a wide range of diseases," said Allison Wey.  "I'm excited to join the Regulus team in advancing its broad portfolio."

Prior to joining Regulus, Ms. Wey was Vice President, Investor Relations for Durata Therapeutics up until its acquisition by Actavis.  Before Durata, Ms. Wey served as Vice President, Investor Relations and Corporate Affairs at Par Pharmaceuticals from 2007 until its acquisition by TPG.  Ms. Wey also has extensive experience in media relations and corporate communications including working as VP, Investor Relations at Boron, LePore & Associates, Senior VP at Edelman Financial Worldwide, Managing Director, Financial Communications at Hill & Knowlton, and Associate Director, Equity Capital Markets at Bear, Stearns & Co. Inc. 

About Regulus

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs.  Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a maturing microMarkersSM biomarkers platform and a rich intellectual property estate to retain its leadership in the microRNA field.  Regulus is developing RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 for the treatment of chronic hepatitis C virus infection, and RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy.  In addition, RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of NASH in patients with type 2 diabetes/pre-diabetes, has entered Phase I clinical development through its strategic alliance with AstraZeneca.  Regulus is also advancing several programs toward clinical development in renal, hepatic and central nervous systems diseases, both independently and with our strategic alliance partners, Sanofi and AstraZeneca.  Regulus' commitment to innovation has resulted in multiple peer-reviewed publications in notable scientific journals and has resulted in the formation of strategic alliances with AstraZeneca and Sanofi.  Regulus maintains its corporate headquarters in La Jolla, CA.  For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Regulus to undertake certain activities and accomplish certain, the projected timeline of clinical development activities, and expectations regarding future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics and biomarkers being discovered and developed by Regulus.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  These and other risks concerning Regulus' financial position and programs are described in additional detail in Regulus filings with the Securities and Exchange Commission.  All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Logo - http://photos.prnewswire.com/prnh/20160519/370141LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/regulus-appoints-allison-wey-as-vice-president-investor-relations--corporate-communications-300272578.html

SOURCE Regulus Therapeutics Inc.

For further information: Investor Relations Contact, Allison Wey, 858-202-6321, awey@regulusrx.com OR Media Contact, Liz Bryan, Spectrum Science, 202-955-6222 x2526, lbryan@spectrumscience.com